These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 10594481)

  • 1. The selective oestrogen receptor modulation: evolution and clinical applications.
    Purdie DW; Beardsworth SA
    Br J Clin Pharmacol; 1999 Dec; 48(6):785-92. PubMed ID: 10594481
    [No Abstract]   [Full Text] [Related]  

  • 2. Raloxifene, arterial function and Ockham's razor.
    Vlachopoulos C; Xaplanteris P; Stefanadis C
    Vascul Pharmacol; 2013 Jan; 58(1-2):1-2. PubMed ID: 23164715
    [No Abstract]   [Full Text] [Related]  

  • 3. Selective oestrogen receptor modulators--current and future brain and behaviour applications.
    Halbreich U; Kahn LS
    Expert Opin Pharmacother; 2000 Dec; 1(7):1385-98. PubMed ID: 11249472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Teasing out effects of estrogen on the brain.
    Friedrich MJ
    JAMA; 2002 Jan; 287(1):29-30. PubMed ID: 11754687
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular effects of raloxifene hydrochloride.
    Saitta A; Morabito N; Frisina N; Cucinotte D; Corrado F; D'Anna R; Altavilla D; Squadrito G; Minutoli L; Arcoraci V; Cancellieri F; Squadrito F
    Cardiovasc Drug Rev; 2001; 19(1):57-74. PubMed ID: 11314601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast.
    Pickar JH; Komm BS
    Post Reprod Health; 2015 Sep; 21(3):112-21. PubMed ID: 26289836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raloxifene revisited.
    Clarkson TB
    Fertil Steril; 2002 Mar; 77(3):445-7. PubMed ID: 11872191
    [No Abstract]   [Full Text] [Related]  

  • 8. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants.
    Lippman ME; Krueger KA; Eckert S; Sashegyi A; Walls EL; Jamal S; Cauley JA; Cummings SR
    J Clin Oncol; 2001 Jun; 19(12):3111-6. PubMed ID: 11408508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease.
    Jordan VC; Gapstur S; Morrow M
    J Natl Cancer Inst; 2001 Oct; 93(19):1449-57. PubMed ID: 11584060
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women.
    Blum A; Schenke WH; Hathaway L; Mincemoyer R; Csako G; Waclawiw MA; Cannon RO
    Am J Cardiol; 2000 Oct; 86(8):892-5. PubMed ID: 11024411
    [No Abstract]   [Full Text] [Related]  

  • 11. [Physiopathology of bone loss and pharmacologic approach of selective estrogen receptor modulators].
    de Vernejoul MC; Cohen-Solal M; Bénichou O
    Joint Bone Spine; 2000; 67 Suppl 1():7s-13s. PubMed ID: 10769109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estrogen, selective estrogen receptor modulation, and coronary heart disease: something or nothing.
    Jordan VC
    J Natl Cancer Inst; 2001 Jan; 93(1):2-4. PubMed ID: 11136828
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.
    Christodoulakos GE; Lambrinoudaki IV; Panoulis CP; Papadias CA; Kouskouni EE; Creatsas GC
    Gynecol Endocrinol; 2004 May; 18(5):244-57. PubMed ID: 15346660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene and cardiovascular health: its relationship to lipid and glucose metabolism, hemostatic and inflammation factors and cardiovascular function in postmenopausal women.
    Francucci CM; Camilletti A; Boscaro M
    Curr Pharm Des; 2005; 11(32):4187-206. PubMed ID: 16375740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of selective estrogen receptor modulators by their gene expression fingerprints.
    Zajchowski DA; Kauser K; Zhu D; Webster L; Aberle S; White FA; Liu HL; Humm R; MacRobbie J; Ponte P; Hegele-Hartung C; Knauthe R; Fritzemeier KH; Vergona R; Rubanyi GM
    J Biol Chem; 2000 May; 275(21):15885-94. PubMed ID: 10748166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action and preclinical profile of raloxifene, a selective estrogen receptor modulation.
    Bryant HU
    Rev Endocr Metab Disord; 2001 Jan; 2(1):129-38. PubMed ID: 11704975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the selective estrogen receptor modulator, raloxifene, on carotid artery pulsatility index in postmenopausal women.
    Setacci C; la Marca A; Agricola E; Morgante G; Setacci F; Cappelli A; Petraglia F; De Leo V
    Am J Obstet Gynecol; 2002 Apr; 186(4):832-5. PubMed ID: 11967516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The selective oestrogen receptor modulators idoxifene and raloxifene have fundamentally different cell-specific oestrogen-response element (ERE)-dependent/independent mechanisms in vitro.
    Nuttall ME; Fisher PW; Suva LJ; Gowen M
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S63-4. PubMed ID: 11056323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134).
    Ning M; Zhou C; Weng J; Zhang S; Chen D; Yang C; Wang H; Ren J; Zhou L; Jin C; Wang MW
    Br J Pharmacol; 2007 Jan; 150(1):19-28. PubMed ID: 17115070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.
    Ang WC; Farrell E; Vollenhoven B
    Climacteric; 2001 Dec; 4(4):284-92. PubMed ID: 11770184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.